Literature DB >> 33791981

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.

Bi-Feng Yuan1.   

Abstract

Gain-of-function mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) were demonstrated to induce the production and accumulation of oncometabolite 2-hydroxyglutarate (2HG). 2HG is a potent competitor of α-ketoglutarate (α-KG) and can inhibit multiple α-KG-dependent dioxygenases that are critical for regulating the metabolic and epigenetic state of cells. The accumulation of 2HG contributes to elevated risk of malignant tumors. 2HG carries an asymmetric carbon atom in its carbon backbone and therefore occurs in two enantiomers, D-2-hydroxyglutarate (D-2HG) and L-2-hydroxyglutarate (L-2HG). Each enantiomer is produced and metabolized in independent biochemical pathway and catalyzed by different enzymes. The accurate diagnosis of 2HG-related diseases relies on determining the configuration of the two enantiomers. Quantitative methods for analysis of D-2HG and L-2HG have been well developed. These analytical strategies mainly include the use of chiral chromatography medium to facilitate chromatographic separation of enantiomers prior to spectroscopy or mass spectrometry analysis and the use of chiral derivatization reagents to convert the enantiomers to diastereomers with differential physical and chemical properties that can improve their chromatographic separation. Here, we summarize and discuss these established methods for analysis of total 2HG as well as the determination of the enantiomers of D-2HG and L-2HG.

Entities:  

Keywords:  2-Hydroxyglutarate; Chiral derivatization; Enantiomer; Gas chromatography-mass spectrometry; Liquid chromatography-mass spectrometry; Oncometabolite

Mesh:

Substances:

Year:  2021        PMID: 33791981     DOI: 10.1007/978-3-030-51652-9_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  73 in total

Review 1.  Engineering Cellular Metabolism.

Authors:  Jens Nielsen; Jay D Keasling
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

2.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

Review 3.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

4.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

5.  R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.

Authors:  Dan Ye; Shenghong Ma; Yue Xiong; Kun-Liang Guan
Journal:  Cancer Cell       Date:  2013-03-18       Impact factor: 31.743

Review 6.  Influence of metabolism on epigenetics and disease.

Authors:  William G Kaelin; Steven L McKnight
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

7.  2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Authors:  Genglin Jin; Zachary J Reitman; Ivan Spasojevic; Ines Batinic-Haberle; Jian Yang; Oleg Schmidt-Kittler; Darell D Bigner; Hai Yan
Journal:  PLoS One       Date:  2011-02-04       Impact factor: 3.752

Review 8.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.

Authors:  Rob A Cairns; Tak W Mak
Journal:  Cancer Discov       Date:  2013-06-24       Impact factor: 38.272

9.  The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.

Authors:  Dinesh Rakheja; L Jeffrey Medeiros; Scott Bevan; Weina Chen
Journal:  Front Oncol       Date:  2013-07-02       Impact factor: 6.244

10.  Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Authors:  William A Flavahan; Yotam Drier; Brian B Liau; Shawn M Gillespie; Andrew S Venteicher; Anat O Stemmer-Rachamimov; Mario L Suvà; Bradley E Bernstein
Journal:  Nature       Date:  2015-12-23       Impact factor: 49.962

View more
  1 in total

1.  A D-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR.

Authors:  Dan Xiao; Wen Zhang; Xiaoting Guo; Yidong Liu; Chunxia Hu; Shiting Guo; Zhaoqi Kang; Xianzhi Xu; Cuiqing Ma; Chao Gao; Ping Xu
Journal:  Nat Commun       Date:  2021-12-07       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.